Buscar
Adial Pharmaceuticals Inc
ADILAñadir a la lista de seguimiento
3.360USD
+0.070+2.13%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
5.07MCap. mercado
PérdidaP/E TTM
Más Datos de Adial Pharmaceuticals Inc Compañía
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Información de Adial Pharmaceuticals Inc
Símbolo de cotizaciónADIL
Nombre de la empresaAdial Pharmaceuticals Inc
Fecha de salida a bolsaJul 27, 2018
Director ejecutivoClaiborne (Cary J)
Número de empleados5
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 27
Dirección1180 Seminole Trail
CiudadCHARLOTTESVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal22901
Teléfono14344229800
Sitio Webhttps://www.adialpharma.com/
Símbolo de cotizaciónADIL
Fecha de salida a bolsaJul 27, 2018
Director ejecutivoClaiborne (Cary J)
Ejecutivos de Adial Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.42K
+93.98%
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
26.52K
+99.96%
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
17.32K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
9.21K
+99.70%
Mr. J. Kermit Anderson
Mr. J. Kermit Anderson
Independent Director
Independent Director
--
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.42K
+93.98%
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
26.52K
+99.96%
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
17.32K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
9.21K
+99.70%
Mr. J. Kermit Anderson
Mr. J. Kermit Anderson
Independent Director
Independent Director
--
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Adial Pharmaceuticals Inc?
Los cinco principales accionistas de Adial Pharmaceuticals Inc son: Mr. Cary J. Claiborne
¿Cuántas instituciones poseen acciones de Adial Pharmaceuticals Inc (ADIL)?
A fecha de 2026Q1, 34 instituciones poseen acciones de Adial Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 141.23K, lo que representa el 9.89% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 100332.00.